Grete F. Lauritzsen

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · Blood · 2008 · 624 citations · Full text

Medicine, Hematology, Oncology +13

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

Francesco d’Amore, Thomas Relander, Grete F. Lauritzsen et al. · Journal of Clinical Oncology · 2012 · 590 citations

Medicine, Oncology, Cell Therapy +12

Nordic <scp>MCL</scp>2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by <scp>BEAM</scp> or <scp>BEAC</scp> + autologous stem‐cell support: still very long survival but late relapses do occur

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · British Journal of Haematology · 2012 · 272 citations

Medicine, Immunology, Oncology +13

15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (<scp>MCL</scp>2): prolonged remissions without survival plateau

Christian Winther Eskelund, Arne Kolstad, Mats Jerkeman et al. · British Journal of Haematology · 2016 · 215 citations · Full text

Medicine, Oncology, Cell Therapy +12

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · Blood · 2009 · 185 citations

Medicine, Immunology, Oncology +10